In a regulatory filing yesterday, Baxter International provided an update on the planned separation of its Kidney Care business. “Consistent with Baxter’s commitment to evaluate strategic options in the interest of maximizing stockholder value, Baxter disclosed that it has been in recent discussions with select private equity investors to explore a potential sale of the Kidney Care asset in lieu of the proposed spinoff of that business. No final decision on the separation structure has been made and Baxter continues to make progress on the previously announced proposed spinoff of the Kidney Care business. Regardless of the separation structure ultimately selected, Baxter has expressed its commitment to separating the Kidney Care business in the second half of 2024,” the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BAX:
- Baxter International Weighs Sale Over Spinoff for Kidney Care
- Baxter call volume above normal and directionally bullish
- Baxter price target raised to $54 from $52 at Barclays
- New Share Price & Shareholder Rights Risk for Baxter International Inc – What’s the Latest?
- Baxter price target raised to $42 from $35 at Deutsche Bank